You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Moyamoya in a Child Treated With Interferon for Recurrent Osteosarcoma

Buchbinder, David MD, MSHS*; Steinberg, Gary MD, PhD; Linetsky, Michael MD; Casillas, Jacqueline MD, MSHS§

Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e3181e5e1db
Clinical and Laboratory Observations
Abstract

Moyamoya is a cerebral vasculopathy of unknown etiology rarely described as a late effect after the treatment of childhood cancer. We describe a 12-year-old female who developed moyamoya after the completion of systemic chemotherapy, surgery, and adjuvant interferon α for osteosarcoma with pulmonary metastases. Given the importance of characterizing late effects after the treatment of childhood cancer, the potential role of interferon α in the development of moyamoya is discussed.

Author Information

*Division of Hematology, Department of Pediatrics, Children's Hospital of Orange County, Main Street, Orange

Department of Neurosurgery, Stanford University School of Medicine, Pasteur Drive, Stanford

Department of Radiology

§Division of Hematology/Oncology, Department of Pediatrics, David Geffen School of Medicine at UCLA, Le Conte Avenue, Los Angeles, CA

Reprints: David Buchbinder, MD, MSHS, Division of Hematology, Department of Pediatrics, Children's Hospital of Orange County, Main Street, 455 S. Main Street, Orange (e-mail: dbuchbinder@choc.org).

Received for publication August 18, 2009; accepted April 21, 2010

© 2010 Lippincott Williams & Wilkins, Inc.